Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

OncoZenge

5.70 SEK

-1.72 %

Less than 1K followers

ONCOZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for OncoZenge

202020212022202320242025
Revenue2.7
growth-%
EBITDA-0.8-4.9-43.6-15.9-8.7-
EBIT-0.8-4.9-43.6-15.9-8.7-15.8
Profit before taxes-0.8-4.9-43.6-15.9-8.7-15.9
Net income-0.8-3.9-46.7-15.9-8.7-15.9
EPS-0.05-0.33-3.98-1.36-0.74-1.31
Dividend0.000.000.000.000.000.00
Dividend ratio-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %

Profitability and return on capital

202020212022202320242025
EBITDA-%
EBIT-%-592.6 %
ROE-2.7 %-4.8 %-137.3 %-85.3 %-87.3 %-188.0 %
ROI-2.1 %-4.6 %-126.5 %-78.2 %-76.0 %-65.3 %
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.